7
20
Growth Score 7 in past quarter
-18 pts
Heat Score 20 in past quarter
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
761378
PolTREG is a biotechnology company.
- Dan Shelly: Chief Business Development Officer
Adrian Bot: Scientific AdvisorPast Role: Kite Pharma, Vice President, Translational Medicine
Immuthera
About the Company
PolTREG’s four most advanced projects are already in the clinical stage of development in the areas of type 1 diabetes and multiple sclerosis. The portfolio also includes projects based on the next generation of genetically modified T-regulatory lymphocytes. The PolTREG team consists of experienced managers, biotechnology specialists and
scientists. The founders have over 17 years of experience in the use of T-regulatory cells in the treatment of autoimmune diseases. The Company’s Scientific Advisory Board includes key world-class opinion leaders.